{"name":"Clinigen, Inc.","slug":"clinigen-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"High Dose Interleukin-2","genericName":"High Dose Interleukin-2","slug":"high-dose-interleukin-2","indication":"Other","status":"marketed"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"vemurafenib + HD IL-2","genericName":"vemurafenib + HD IL-2","slug":"vemurafenib-hd-il-2","indication":"Metastatic melanoma with BRAF V600E mutation","status":"marketed"}]}],"pipeline":[{"name":"High Dose Interleukin-2","genericName":"High Dose Interleukin-2","slug":"high-dose-interleukin-2","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"vemurafenib + HD IL-2","genericName":"vemurafenib + HD IL-2","slug":"vemurafenib-hd-il-2","phase":"marketed","mechanism":"Vemurafenib inhibits mutant BRAF kinase to block tumor cell proliferation, while high-dose IL-2 activates the immune system to enhance anti-tumor immunity.","indications":["Metastatic melanoma with BRAF V600E mutation"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxQX1Zla1ZKU0U3cVpjT3NZd29QcWlXYlB0a09NcERrc0gxekZNU0FoMndXNW9NVGozdnc0OFRXLWtSSk9nNVlkWVBFcUZucWtFdl9EdGhDVmd6OWlRYkJNTGZJWVFnaHlwMlEtSHRaVEQ1eU9fdWNQcW5nNG02U043OTN2d2FhRXBQLWpvR1BoVndHaWh2aVBxaHVLbzBPbmNWM2stRHpKamhJamRjRmpuVmtwOWlKTVN5TzZ0dVRhdWREb0V5dzUw?oc=5","date":"2026-03-31","type":"pipeline","source":"Business Wire","summary":"MaaT Pharma Announces 2025 Annual Results and Provides Business Updates - Business Wire","headline":"MaaT Pharma Announces 2025 Annual Results and Provides Business Updates","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxOdjZndTJLUlZWX3N4LWhIbXktTVBURHk4dG9SY2V4M01va2kxWDQ3UkhTcHJmX2dRWkdrcURvV2NzZVF4Z2dYZnhvbjkxMnpOYzBINko5dFRvcWl0b191eUQ5RFE2UFNnNWZ3c05IX3p1YlJSZjZ4M05WYkR4N1MxNnZrUENhUDg?oc=5","date":"2026-03-09","type":"pipeline","source":"Yahoo Finance","summary":"MaaT Pharma to Present Four Abstracts at the 52nd European Bone Marrow Transplantation Annual Meeting and to Highlight Clinigen-Hosted Industry Symposium on acute GvHD Management - Yahoo Finance","headline":"MaaT Pharma to Present Four Abstracts at the 52nd European Bone Marrow Transplantation Annual Meeting and to Highlight C","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxQR2hFenZqQjR6VXVkTFBxZXR4RXZqTUNlVEd6Wkh0NWM5RUtMUkc3M2dBdEpIVnJ3VFBkRE5DX2p4S2JBaFk3NTRsTEZ3akNEdXV2aVNGanhzTkdvbkIxSk9kNEd4aHB1UGdaVUlpZ0lZVy1nbk9fWFdDMkNZWE1XMU13WTNTTW1sc0NKRw?oc=5","date":"2026-01-26","type":"pipeline","source":"Yahoo Finance","summary":"Comparator Drug Sourcing Global Market Review 2021-2025 and Forecast 2026-2031 Featuring Clinigen, BAP Pharma Group, Thermo Fisher Scientific, Laboratory Corporation of America, Catalent and More - Ya","headline":"Comparator Drug Sourcing Global Market Review 2021-2025 and Forecast 2026-2031 Featuring Clinigen, BAP Pharma Group, The","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxPaVFHcjVRaXZwSFFIY3NveThCWklGcHItT1hJckFRc3ZWbm50NW5KSzhlbXlreGgyWDJubFB0V2psdms3emdHeGZQRGJfTU9BUDVJLTRzdERqdXo2UDVyUkkzdFRsSEs4V0ZYRHpveG5pZnU5d0lQejJMMjY0d1hPNk5yTS0tdXREQ3V3?oc=5","date":"2025-11-03","type":"earnings","source":"Yahoo Finance","summary":"MaaT Pharma Reports Financial Results for the Third Quarter 2025 and Provides Financing Update - Yahoo Finance","headline":"MaaT Pharma Reports Financial Results for the Third Quarter 2025 and Provides Financing Update","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxPOVM2OVZXNHM4QWJGNm82WS1kbEJBSlV1TlVncFpkS0g3SXdOeGZqMU96c3U5R25vYUg0V2kyM1RBWWxLMnhjdjQ2bVBVbkQ4ZW0zNGRBU2NMa0xoVkVJaFk1TG9hV1FpeWF3UWlJdzF1UXZVazZFWE92amNzTnNfd0RqT2VuV1pSNXd5NzJBWC1DbTJmdEFOX3hMY1VYQTdyaS1TeGVRRV9CUQ?oc=5","date":"2025-09-29","type":"pipeline","source":"Axios","summary":"Scoop: Clinigen acquiring SSI Strategy for high-teens multiple - Axios","headline":"Scoop: Clinigen acquiring SSI Strategy for high-teens multiple","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxPREpZLVN6aHR6X3BLci11MmVkMGEycFg5M2U3WUZma0pHM0VESHJTTWtxM3hVbllPdHBtLS1TYWZUNUlQZ0NuWGpOWl9lZlhNZ1lJMjJuMWllN0xnTEZoSjhaamtaQldLOUxxZzVWOTE5SFdCa0VvY2NUODE1WWZkT2plSVdCaVpmelNEMjFjQ19oQm1fWmJqSGxLVUQySmk4dEFKQVo3bGY?oc=5","date":"2025-08-01","type":"pipeline","source":"pharmaphorum","summary":"Changing Faces – Board of Director and Advisory Board hires for June 2025 - pharmaphorum","headline":"Changing Faces – Board of Director and Advisory Board hires for June 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxOSU1FbkFWdEZJR3lUemhYZzZZUzFPRExVRlp3YTh4dlh6eWdJTE9wS0U3NnRMbEZ1eThJTkdyeDF0TnpNaDMxMFNTaF9OZXY3UF93RzZxeWFhZGd3cmNwb3pSRWhhaWhCNnQzSV80S1RCTmR2bzVmWklMX2tYOUg2dlJLcTBPaEJ6NHlSSGdVQjVWNlZwOFhQZ2lka0VaM1dTLW5PZUtELXhJeDN1ODBYTU5B?oc=5","date":"2025-05-01","type":"pipeline","source":"Contract Pharma","summary":"Clinigen Appoints Nihad Hasagic as SVP, Clinigen Lifecycle Services - Contract Pharma","headline":"Clinigen Appoints Nihad Hasagic as SVP, Clinigen Lifecycle Services","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxPUEpMV0tFX3drNm1XLW9TZHNNTVVtaGdUbVdoWmtCVnlMRFlBTThyZTVwVmZSajZqVVdueFlDcTc3RXg5SVJxUXRfMXoyV0VIY3RfQ0dndDZENHdWRVh0UlVGWGJ5TUVqTGlpNmVJd0hFQ0l0YnNSYlp3RDlWSVBWWFJpaWJPdUdL?oc=5","date":"2023-08-11","type":"pipeline","source":"Pharmaceutical Technology","summary":"Clinigen clears out cancer therapies in line with latest growth strategy - Pharmaceutical Technology","headline":"Clinigen clears out cancer therapies in line with latest growth strategy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxQM2hMR2dPd1ZVbE55bmlGa29NdFV5MEZWUmxRUFdPSVF5cHo3VzJjbnQ4N0MyaVY0cjVYVmJwaXl1SzdoSGxySGJieUplYlpFUWFpeDhVYmVnZ2Vra3ZJT1RFRjlFR29fNnVDS3Z3NVFyN1d5YmNvUkxzYXhKSjVJWGYyVmdJQQ?oc=5","date":"2022-05-25","type":"pipeline","source":"Contract Pharma","summary":"Clinigen Expands U.S. Site Capacity - Contract Pharma","headline":"Clinigen Expands U.S. Site Capacity","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxQTG5rNlROTDEza2VWQ01tOWUxQ2dhcHdtU01IbDZib2ZCbWk5MkozWUhtSG9saXBaOUsyYmd0V0tuS1Y2X29ZX2lZV1F2eWg4WXZMLVIwdHk2NkQ5OUJ6dVA2QnpoWkJvQnNsa1BJTWNFZmVlVnRVUXBDWTN5dWdlcVgyOVFscnN2bG8xWkxNMmU1VmhvYTJ2SDRWZjMtUdIBVkFVX3lxTE0zRVJCcGE0WkhEa01VZzk1X0RIbk5mZ3lSWHZ6RWw5WUt5anNUeU1fYWVVbUc4ajhKSHlzV0pXQTk2Z3Z4QUNtR3plQ2xzbE95VTNfc1F3?oc=5","date":"2021-12-08","type":"deal","source":"Law360","summary":"3 Firms Lead £1.2B PE Buyout Of British Pharma Co. Clinigen - Law360","headline":"3 Firms Lead £1.2B PE Buyout Of British Pharma Co. Clinigen - Law360","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxQSEs3MDd1cC0tRTlnZkZScUdobTBpUElodmxLNFdCOFdpME1QYUVyOWZET3pieXo2MVVkUmRkdTIzWTRaQlhhMkpQTUdDQklmVVY0QkwxZnpVWUVQckRIZlpvcUVvNVc0LURYYnh3am8wYjJvOXlrN1ZUNUdJcm9GT3JqVkNqVHRtLWxFcHF6TFFSSGxLcmxCRnZKazdVYmtZNjlTT0FBeXpJOWpidVU5VUhfcE84TlNzc0VqS1pzVy1TemNXOFVVMXFwZw?oc=5","date":"2021-12-08","type":"pipeline","source":"The Guardian","summary":"Cancer drug specialist Clinigen latest big UK firm to be taken private - The Guardian","headline":"Cancer drug specialist Clinigen latest big UK firm to be taken private","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxQa1VlMENOQmU4Zl9ZbnhZZ1FpT09aSmVpTG5CQ1hwSFRGd2s2TmFRcHVxUUc5cHpfbXVPSGlOTVB3ekxkYXZ0Q09DaDJHckRZelNhREFKSG9NVTU1ekhwNi1HaWlycWhoSnRYeUJwUy1OdVh5NTIxWXE3ODl5THZnZ0tTU1pBaktzaVJ0MWVoNTlwcDBEcFlfaXB4bVNJNUVGM2kxYV9Ba1hEQUNVSzc5TzhYMmdCODZvVHlVNGRlX21aVmwyNkJuUDV1bDdkVFZlb3BFc1ZvOXl5b1Q1UVdqRmMtUGFCdVpKY1E?oc=5","date":"2021-09-22","type":"pipeline","source":"PR Newswire","summary":"Secura Bio Announces European Distribution Agreement for COPIKTRA® with Clinigen Healthcare Limited - PR Newswire","headline":"Secura Bio Announces European Distribution Agreement for COPIKTRA® with Clinigen Healthcare Limited","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"marketed":2},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}